Michael L. West
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael L. West has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Kathy Nicholls
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
5 shared publications - Ales Linhart
2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague
2 shared publications Ana Jovanovic
Mark Holland Metabolic Unit, Northern Care Alliance NHS Foundation Trust, Salford, UK
2 shared publications- Bojan Vujkovac
Centre for Fabry Disease, General Hospital Slovenj Gradec, 2380 Slovenj Gradec, Slovenia
2 shared publications Daniel G. Bichet
Correspondence to: Dr. Michael L. West, Division of Nephrology, Department of Medicine, Dalhousie University, B06 CCR, QE II Health Sciences Centre, 5790 University Ave, Halifax, NS B3H 1V7, Canada
2 shared publications- Derralynn A. Hughes
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, London, UK
2 shared publications
Latest Publications
- Open Access
- 10 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension
In Fabry disease (FD, OMIM #301500), a rare lysosomal storage disorder, the glucosylceramide synthase inhibitor lucerastat acts as substrate reduction therapy. The Phase 3, prospective, double-blind, placebo-controlled, 6-month, randomized clinical trial, MODIFY (NCT03425539), aimed to evaluate the efficacy, safety, and tolerability of lucerastat in adults with FD with moderate-to-severe neuropathic pain. The single-arm, open-label extension (OLE) (NCT03737214) evaluated the longer-term safety and tolerability of lucerastat over 72 months. Lucerastat 1000 mg twice daily (n = 80), compared with placebo (n = 37), failed to affect neuropathic pain at Month-6, with no significant difference between treatment groups (LSM difference –0.42 [95% CI –1.23, 0.40], p = 0.32) (primary endpoint). In contrast, a decrease in baseline plasma Gb3 was observed at Month-6 in lucerastat-treated participants but not placebo-treated participants (LSM difference –873.53 ng/mL [95% CI –1097.53, –649.53], p < 0.0001; NS due to hierarchical testing). In an unplanned OLE Month-18 interim analysis, the eGFR slope (mL/min/1.73m2/year) in 93 participants with pre- and post-randomization (23-month median lucerastat exposure) eGFR data was –3.50 (–5.04, –1.969) and –1.48 (–2.64, –0.33), respectively. Lucerastat was safe and well tolerated. Lucerastat’s strong pharmacodynamic effect did not translate into an effect on neuropathic pain. The potential effect of lucerastat on renal function requires further investigation (Trial registration NCT03425539, NCT03737214; 2017-003369-85, 2018-002210-12. The studies were sponsored by Idorsia Pharmaceuticals Ltd).
- 10 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension
In Fabry disease (FD, OMIM #301500), a rare lysosomal storage disorder, the glucosylceramide synthase inhibitor lucerastat acts as substrate reduction therapy. The Phase 3, prospective, double-blind, placebo-controlled, 6-month, randomized clinical trial, MODIFY (NCT03425539), aimed to evaluate the efficacy, safety, and tolerability of lucerastat in adults with FD with moderate-to-severe neuropathic pain. The single-arm, open-label extension (OLE) (NCT03737214) evaluated the longer-term safety and tolerability of lucerastat over 72 months. Lucerastat 1000 mg twice daily (n = 80), compared with placebo (n = 37), failed to affect neuropathic pain at Month-6, with no significant difference between treatment groups (LSM difference –0.42 [95% CI –1.23, 0.40], p = 0.32) (primary endpoint). In contrast, a decrease in baseline plasma Gb3 was observed at Month-6 in lucerastat-treated participants but not placebo-treated participants (LSM difference –873.53 ng/mL [95% CI –1097.53, –649.53], p < 0.0001; NS due to hierarchical testing). In an unplanned OLE Month-18 interim analysis, the eGFR slope (mL/min/1.73m2/year) in 93 participants with pre- and post-randomization (23-month median lucerastat exposure) eGFR data was –3.50 (–5.04, –1.969) and –1.48 (–2.64, –0.33), respectively. Lucerastat was safe and well tolerated. Lucerastat’s strong pharmacodynamic effect did not translate into an effect on neuropathic pain. The potential effect of lucerastat on renal function requires further investigation (Trial registration NCT03425539, NCT03737214; 2017-003369-85, 2018-002210-12. The studies were sponsored by Idorsia Pharmaceuticals Ltd).
- Open Access
- 11 July 2024
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 3 (3)
Fabry nephropathy: a treatable cause of chronic kidney disease
Fabry disease is a rare X-linked inborn error of metabolism that has a high prevalence of chronic kidney disease (CKD) and renal failure. It is due to the deficiency of the α-galactosidase A (α-Gal) lysosomal enzyme with subsequent accumulation of globotriaosylceramide (Gb3) in lysosomes. In the kidney, the podocyte is the main target of this disease, although all cell types are involved. The podocyte, being terminally differentiated, does not replicate and thus accumulates Gb3 throughout life. Podocytes are injured by Gb3, leading to their detachment from the glomerular basement membrane and subsequent loss in the urine. Albuminuria starts in childhood and progresses to overt proteinuria in the teens and 20 s. CKD ensues with adults starting dialysis at an average age of 42 years. Patients have a high prevalence of stroke and cardiomyopathy with hypertrophic change, heart failure, and dysrhythmias. Patient survival is limited in both genders. Diagnosis is based on the demonstration of a low α-Gal activity and a pathogenic GLA mutation. Clinical features are highly variable, which makes recognition of this condition difficult. Treatment with intravenous recombinant human enzyme replacement therapy (ERT) and oral pharmacologic chaperone are available. Control of proteinuria to 0.5 g/day or less is of critical importance to limit progression to end-stage renal disease. Early initiation of treatment gives the best results, but the optimal age to start is uncertain. Fabry nephropathy remains a challenge due to its multisystem nature, difficult diagnosis, and complicated management. It is important as a treatable cause of CKD.
- 11 July 2024
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 3 (3)
Open AccessFabry nephropathy: a treatable cause of chronic kidney disease
Fabry disease is a rare X-linked inborn error of metabolism that has a high prevalence of chronic kidney disease (CKD) and renal failure. It is due to the deficiency of the α-galactosidase A (α-Gal) lysosomal enzyme with subsequent accumulation of globotriaosylceramide (Gb3) in lysosomes. In the kidney, the podocyte is the main target of this disease, although all cell types are involved. The podocyte, being terminally differentiated, does not replicate and thus accumulates Gb3 throughout life. Podocytes are injured by Gb3, leading to their detachment from the glomerular basement membrane and subsequent loss in the urine. Albuminuria starts in childhood and progresses to overt proteinuria in the teens and 20 s. CKD ensues with adults starting dialysis at an average age of 42 years. Patients have a high prevalence of stroke and cardiomyopathy with hypertrophic change, heart failure, and dysrhythmias. Patient survival is limited in both genders. Diagnosis is based on the demonstration of a low α-Gal activity and a pathogenic GLA mutation. Clinical features are highly variable, which makes recognition of this condition difficult. Treatment with intravenous recombinant human enzyme replacement therapy (ERT) and oral pharmacologic chaperone are available. Control of proteinuria to 0.5 g/day or less is of critical importance to limit progression to end-stage renal disease. Early initiation of treatment gives the best results, but the optimal age to start is uncertain. Fabry nephropathy remains a challenge due to its multisystem nature, difficult diagnosis, and complicated management. It is important as a treatable cause of CKD.
- 17 October 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (23) , 1421-1437
Fabry Disease Biomarkers in Patients Switched From Enzyme-Replacement Therapy to Migalastat Oral Chaperone Therapy
Background: A biomarker profile was evaluated longitudinally in patients with Fabry disease switched from enzyme replacement therapy (ERT) to migalastat. Methods: Sixteen Gb3 isoforms and eight lys... Graphical abstract
- 17 October 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (23) , 1421-1437
Fabry Disease Biomarkers in Patients Switched From Enzyme-Replacement Therapy to Migalastat Oral Chaperone Therapy
Background: A biomarker profile was evaluated longitudinally in patients with Fabry disease switched from enzyme replacement therapy (ERT) to migalastat. Methods: Sixteen Gb3 isoforms and eight lys... Graphical abstract
- 26 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 139 (1) , 107541
Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
- 26 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 139 (1) , 107541
Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
- Open Access
- 17 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4810
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, which, without treatment, can cause significant renal dysfunction. We evaluated the effects of enzyme replacement therapy with agalsidase alfa on renal decline in patients with Fabry disease using data from the Fabry Outcome Survey (FOS) registry. Male patients with Fabry disease aged >16 years at agalsidase alfa start were stratified by low (≤0.5 g/24 h) or high (>0.5 g/24 h) baseline proteinuria and by ‘classic’ or ‘non-classic’ phenotype. Overall, 193 male patients with low (n = 135) or high (n = 58) baseline proteinuria were evaluated. Compared with patients with low baseline proteinuria, those with high baseline proteinuria had a lower mean ± standard deviation baseline eGFR (89.1 ± 26.2 vs. 106.6 ± 21.8 mL/min/1.73 m2) and faster mean ± standard error eGFR decline (−3.62 ± 0.42 vs. −1.61 ± 0.28 mL/min/1.73 m2 per year; p < 0.0001). Patients with classic Fabry disease had similar rates of eGFR decline irrespective of baseline proteinuria; only one patient with non-classic Fabry disease had high baseline proteinuria, preventing meaningful comparisons between groups. In this analysis, baseline proteinuria significantly impacted the rate of eGFR decline in the overall population, suggesting that early treatment with good proteinuria control may be associated with renoprotective effects.
- 17 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4810
Open AccessRenoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, which, without treatment, can cause significant renal dysfunction. We evaluated the effects of enzyme replacement therapy with agalsidase alfa on renal decline in patients with Fabry disease using data from the Fabry Outcome Survey (FOS) registry. Male patients with Fabry disease aged >16 years at agalsidase alfa start were stratified by low (≤0.5 g/24 h) or high (>0.5 g/24 h) baseline proteinuria and by ‘classic’ or ‘non-classic’ phenotype. Overall, 193 male patients with low (n = 135) or high (n = 58) baseline proteinuria were evaluated. Compared with patients with low baseline proteinuria, those with high baseline proteinuria had a lower mean ± standard deviation baseline eGFR (89.1 ± 26.2 vs. 106.6 ± 21.8 mL/min/1.73 m2) and faster mean ± standard error eGFR decline (−3.62 ± 0.42 vs. −1.61 ± 0.28 mL/min/1.73 m2 per year; p < 0.0001). Patients with classic Fabry disease had similar rates of eGFR decline irrespective of baseline proteinuria; only one patient with non-classic Fabry disease had high baseline proteinuria, preventing meaningful comparisons between groups. In this analysis, baseline proteinuria significantly impacted the rate of eGFR decline in the overall population, suggesting that early treatment with good proteinuria control may be associated with renoprotective effects.
- Open Access
- 20 September 2021
- Published by Springer Nature in Drugs in R&D
- Vol. 21 (4) , 385-397
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process
Background and Objective Fabry disease, an X-linked lysosomal storage disorder characterized by absent or reduced alpha-galactosidase activity, is a lifelong disease that impairs patients’ quality of life. Patients with Fabry disease have a considerably shortened lifespan, with mortality being mainly due to renal failure, cardiovascular disease, or cerebrovascular disease. Enzyme replacement therapy with agalsidase alfa has been shown to attenuate the renal, cardiovascular, and neuropathic disease progression associated with Fabry disease. The objective of this study was to investigate the safety of a new animal component-free version of agalsidase alfa. Methods A phase III/IV, open-label, single-arm, multicenter safety study was conducted in Canadian patients with Fabry disease between August 2011 and September 2017 as a regulatory requirement to assess the safety of agalsidase alfa produced using an animal component-free bioreactor process. Eligible patients had a documented diagnosis of Fabry disease and satisfied current Canadian guidelines for receiving enzyme replacement therapy for Fabry disease. Following treatment with animal component-free bioreactor-processed agalsidase alfa, treatment-emergent adverse events were monitored, and post hoc analyses of infusion-related reactions by antidrug antibody and neutralizing antibody statuses were conducted. The data were analyzed using descriptive statistics. Results A total of 167 patients (mean [standard deviation] age, 48.9 [14.8] years), including six pediatric patients (< 18 years of age), received at least one full or partial infusion of agalsidase alfa animal component-free. Fewer than 5% of treatment-emergent adverse events (212/4446) observed in 40 patients were reported as infusion-related reactions. Antidrug antibody and neutralizing antibody status did not affect the proportion of patients with infusion-related reactions. No clinically significant changes in vital signs were observed in patients over the course of the study. Conclusions Long-term treatment with bioreactor-produced agalsidase alfa animal component-free did not reveal new safety signals in this population of Canadian patients with Fabry disease. The treatment-emergent adverse event profile was consistent with the clinical manifestations of the disease and the known safety profile of roller bottle-produced agalsidase alfa. Clinical Trial Registration ClinicalTrials.gov identifier NCT01298141.
- 20 September 2021
- Published by Springer Nature in Drugs in R&D
- Vol. 21 (4) , 385-397
Open AccessThe Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process
Background and Objective Fabry disease, an X-linked lysosomal storage disorder characterized by absent or reduced alpha-galactosidase activity, is a lifelong disease that impairs patients’ quality of life. Patients with Fabry disease have a considerably shortened lifespan, with mortality being mainly due to renal failure, cardiovascular disease, or cerebrovascular disease. Enzyme replacement therapy with agalsidase alfa has been shown to attenuate the renal, cardiovascular, and neuropathic disease progression associated with Fabry disease. The objective of this study was to investigate the safety of a new animal component-free version of agalsidase alfa. Methods A phase III/IV, open-label, single-arm, multicenter safety study was conducted in Canadian patients with Fabry disease between August 2011 and September 2017 as a regulatory requirement to assess the safety of agalsidase alfa produced using an animal component-free bioreactor process. Eligible patients had a documented diagnosis of Fabry disease and satisfied current Canadian guidelines for receiving enzyme replacement therapy for Fabry disease. Following treatment with animal component-free bioreactor-processed agalsidase alfa, treatment-emergent adverse events were monitored, and post hoc analyses of infusion-related reactions by antidrug antibody and neutralizing antibody statuses were conducted. The data were analyzed using descriptive statistics. Results A total of 167 patients (mean [standard deviation] age, 48.9 [14.8] years), including six pediatric patients (< 18 years of age), received at least one full or partial infusion of agalsidase alfa animal component-free. Fewer than 5% of treatment-emergent adverse events (212/4446) observed in 40 patients were reported as infusion-related reactions. Antidrug antibody and neutralizing antibody status did not affect the proportion of patients with infusion-related reactions. No clinically significant changes in vital signs were observed in patients over the course of the study. Conclusions Long-term treatment with bioreactor-produced agalsidase alfa animal component-free did not reveal new safety signals in this population of Canadian patients with Fabry disease. The treatment-emergent adverse event profile was consistent with the clinical manifestations of the disease and the known safety profile of roller bottle-produced agalsidase alfa. Clinical Trial Registration ClinicalTrials.gov identifier NCT01298141.
- 1 September 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 134 (1-2) , 117-131
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
- 1 September 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 134 (1-2) , 117-131
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S107-S108
Renal and secondary outcomes 1 year after switching from agalsidase alfa to pegunigalsidase alfa for Fabry disease (the BRIDGE study)
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S107-S108
Renal and secondary outcomes 1 year after switching from agalsidase alfa to pegunigalsidase alfa for Fabry disease (the BRIDGE study)
- Open Access
- 1 October 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3705-3715
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
Purpose: Following the publication of 5-year agalsidase alfa enzyme replacement therapy (ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed. Patients and methods: FOS (ClinicalTrials.gov identifier: NCT03289065) data (April 2001 to August 2018) were retrospectively analyzed. Estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) were analyzed after treatment start (baseline) for patients with ≥3 measurements, including baseline and year 10. Results: Median (range) age (years) of the evaluable treated renal cohort at treatment start was 48.8 (17.9–67.3) for females (n=62), 34.4 (18.0–66.8) for males (n=90). With eGFR ≥60 mL/min/1.73 m2 at baseline, mean (95% CI) rate of eGFR change (eGFR/year) over 10 years was relatively stable in females (n=52; −0.55 [−1.12, +0.01]) and slightly declined in males (n=79; −1.99 [−2.45, −1.54]). With impaired kidney function (eGFR 48 g/m2.7 in females, >50 g/m2.7 in males) at baseline, mean (95% CI) LVMI/year slightly increased over 10 years in females (n=18; +1.51 [+0.91, +2.12]) and males (n=14; +0.87 (+0.19, +1.55). Without LVH at baseline, mean (95% CI) LVMI/year was stable in females (n=16; +0.52 [−0.13, +1.17]) and males (n=21; +0.57 [+0.02, +1.13]) over 10 years. Conclusion: Agalsidase alfa-treated patients with 10-year FOS data and preserved kidney function and/or normal LVMI at baseline remained largely stable; those with decreased kidney function or LVH at baseline experienced modest declines in renal function and/or increases in LVMI.
- 1 October 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3705-3715
Open AccessCardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
Purpose: Following the publication of 5-year agalsidase alfa enzyme replacement therapy (ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed. Patients and methods: FOS (ClinicalTrials.gov identifier: NCT03289065) data (April 2001 to August 2018) were retrospectively analyzed. Estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) were analyzed after treatment start (baseline) for patients with ≥3 measurements, including baseline and year 10. Results: Median (range) age (years) of the evaluable treated renal cohort at treatment start was 48.8 (17.9–67.3) for females (n=62), 34.4 (18.0–66.8) for males (n=90). With eGFR ≥60 mL/min/1.73 m2 at baseline, mean (95% CI) rate of eGFR change (eGFR/year) over 10 years was relatively stable in females (n=52; −0.55 [−1.12, +0.01]) and slightly declined in males (n=79; −1.99 [−2.45, −1.54]). With impaired kidney function (eGFR 48 g/m2.7 in females, >50 g/m2.7 in males) at baseline, mean (95% CI) LVMI/year slightly increased over 10 years in females (n=18; +1.51 [+0.91, +2.12]) and males (n=14; +0.87 (+0.19, +1.55). Without LVH at baseline, mean (95% CI) LVMI/year was stable in females (n=16; +0.52 [−0.13, +1.17]) and males (n=21; +0.57 [+0.02, +1.13]) over 10 years. Conclusion: Agalsidase alfa-treated patients with 10-year FOS data and preserved kidney function and/or normal LVMI at baseline remained largely stable; those with decreased kidney function or LVH at baseline experienced modest declines in renal function and/or increases in LVMI.
- 26 August 2019
- Published by JLE in Nephrologie & Therapeutique
- Vol. 15 (5) , 339
Effet néphroprotecteur de l’agalsidase alfa : suivi à 12 ans de patients masculins atteints de la maladie de Fabry
Introduction: Notre objectif était d’évaluer l’impact du traitement par agalsidase alfa sur le déclin du DFGe chez les patients atteints de la maladie de Fabry dans le registre Fabry Outcome Survey (FOS). Méthodes: Nous avons analysé des patients de plus de 16 ans au début de leur traitement par agalsidase alfa (baseline : BL), avec une durée de traitement minimale de 7 ans, au moins 3 mesures de DFGe disponibles, aucun antécédent de dialyse/transplantation et un DFGe à la BL ≥ 45 ml/min/1,73m2. Les patients ont été stratifiés en deux cohortes : atteinte rénale élevée (high renal involvement HRI, protéinurie de BL > 0,5 g/24 h) et atteinte rénale faible (Low Renal Involvement LRI, protéinurie de BL ≤ 0,5 g/24 h). Le DFGe a été calculé à l’aide de la formule CKD-EPI. 138 hommes ont été inclus (108 LRI, 30 HRI), âge moyen 34,0 ans à l’inclusion (intervalle : 16,7–75,9). Résultats obtenus ou attendus La moyenne ±écart type (ET) de la durée du traitement était de 12,4 ± 3,1 années (intervalle : 7,0–18,1) et de 12,3 ± 3,2 années (intervalle : 7,0-17,5) pour LRI et HRI, respectivement. À la BL, la moyenne ± ET du DFGe était de 106,9 ± 22,6 ml/min/1,73m2 pour LRI vs 96,4 ± 25,0 ml/min/1,73m2 pour HRI ; La protéinurie moyenne ± ET était de 0,19 ± 0,12 g/jour pour LRI vs 1,23 ± 0,92 g/jour pour HRI. Le taux annuel moyen de variation du DFGe ± l’erreur type de la moyenne (ETM) était de − 1,43 ± 0,18 ml/min/1,73m2 pour le groupe LRI par rapport à − 2,40 ± 0,36 ml/min/1,73m2 pour le groupe HRI. Conclusion: L’utilisation de l’agalsidase alfa peut être associée à de potentiels effets néphroprotecteurs, conduisant à une stabilisation de la fonction rénale par rapport au déclin attendu chez les patients atteints de maladie de Fabry. Ces résultats peuvent également suggérer que la protéinurie de base est un facteur de risque d’insuffisance rénale.
- 26 August 2019
- Published by JLE in Nephrologie & Therapeutique
- Vol. 15 (5) , 339
Effet néphroprotecteur de l’agalsidase alfa : suivi à 12 ans de patients masculins atteints de la maladie de Fabry
Introduction: Notre objectif était d’évaluer l’impact du traitement par agalsidase alfa sur le déclin du DFGe chez les patients atteints de la maladie de Fabry dans le registre Fabry Outcome Survey (FOS). Méthodes: Nous avons analysé des patients de plus de 16 ans au début de leur traitement par agalsidase alfa (baseline : BL), avec une durée de traitement minimale de 7 ans, au moins 3 mesures de DFGe disponibles, aucun antécédent de dialyse/transplantation et un DFGe à la BL ≥ 45 ml/min/1,73m2. Les patients ont été stratifiés en deux cohortes : atteinte rénale élevée (high renal involvement HRI, protéinurie de BL > 0,5 g/24 h) et atteinte rénale faible (Low Renal Involvement LRI, protéinurie de BL ≤ 0,5 g/24 h). Le DFGe a été calculé à l’aide de la formule CKD-EPI. 138 hommes ont été inclus (108 LRI, 30 HRI), âge moyen 34,0 ans à l’inclusion (intervalle : 16,7–75,9). Résultats obtenus ou attendus La moyenne ±écart type (ET) de la durée du traitement était de 12,4 ± 3,1 années (intervalle : 7,0–18,1) et de 12,3 ± 3,2 années (intervalle : 7,0-17,5) pour LRI et HRI, respectivement. À la BL, la moyenne ± ET du DFGe était de 106,9 ± 22,6 ml/min/1,73m2 pour LRI vs 96,4 ± 25,0 ml/min/1,73m2 pour HRI ; La protéinurie moyenne ± ET était de 0,19 ± 0,12 g/jour pour LRI vs 1,23 ± 0,92 g/jour pour HRI. Le taux annuel moyen de variation du DFGe ± l’erreur type de la moyenne (ETM) était de − 1,43 ± 0,18 ml/min/1,73m2 pour le groupe LRI par rapport à − 2,40 ± 0,36 ml/min/1,73m2 pour le groupe HRI. Conclusion: L’utilisation de l’agalsidase alfa peut être associée à de potentiels effets néphroprotecteurs, conduisant à une stabilisation de la fonction rénale par rapport au déclin attendu chez les patients atteints de maladie de Fabry. Ces résultats peuvent également suggérer que la protéinurie de base est un facteur de risque d’insuffisance rénale.